261 related articles for article (PubMed ID: 8276175)
21. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
Poupon R
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
[TBL] [Abstract][Full Text] [Related]
22. Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol.
Ghonem NS; Auclair AM; Hemme CL; Gallucci GM; de la Rosa Rodriguez R; Boyer JL; Assis DN
Clin Pharmacol Ther; 2020 Dec; 108(6):1213-1223. PubMed ID: 32480421
[TBL] [Abstract][Full Text] [Related]
23. Novel and emerging therapies for cholestatic liver diseases.
Goldstein J; Levy C
Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112
[TBL] [Abstract][Full Text] [Related]
24. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study.
Assis DN; Abdelghany O; Cai SY; Gossard AA; Eaton JE; Keach JC; Deng Y; Setchell KD; Ciarleglio M; Lindor KD; Boyer JL
J Clin Gastroenterol; 2017 Feb; 51(2):e11-e16. PubMed ID: 27428727
[TBL] [Abstract][Full Text] [Related]
25. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.
Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P
Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384
[TBL] [Abstract][Full Text] [Related]
26. Treatment of chronic active hepatitis and primary biliary cirrhosis with ursodeoxycholic acid.
Güldütuna S; Leuschner U; Imhof M; Zimmer G
Z Gastroenterol; 1992 Mar; 30 Suppl 1():49-54. PubMed ID: 1449017
[TBL] [Abstract][Full Text] [Related]
27. [Bile acids in liver diseases--current indications].
Stiehl A
Ther Umsch; 1995 Oct; 52(10):682-6. PubMed ID: 7482380
[TBL] [Abstract][Full Text] [Related]
28. Effect of ursodeoxycholic acid administration on biliary lipid secretion in primary biliary cirrhosis.
Roda E; Mazzella G; Bazzoli F; Villanova N; Minutello A; Simoni P; Ronchi M; Poggi C; Festi D; Aldini R
Dig Dis Sci; 1989 Dec; 34(12 Suppl):52S-58S. PubMed ID: 2598768
[TBL] [Abstract][Full Text] [Related]
29. Drug Therapies for Chronic Cholestatic Liver Diseases.
Wagner M; Fickert P
Annu Rev Pharmacol Toxicol; 2020 Jan; 60():503-527. PubMed ID: 31506007
[TBL] [Abstract][Full Text] [Related]
30. Ileal absorption of bile acids in patients with chronic cholestasis: SeHCAT test results and effect of ursodeoxycholic acid (UDCA).
Chazouillères O; Marteau P; Haniche M; Jian R; Poupon R
Dig Dis Sci; 1996 Dec; 41(12):2417-22. PubMed ID: 9011452
[TBL] [Abstract][Full Text] [Related]
31. Cholic acid and ursodeoxycholic acid therapy in primary biliary cirrhosis. Changes in bile acid patterns and their correlation with liver function.
Güldütuna S; Leuschner M; Wunderlich N; Nickel A; Bhatti S; Hübner K; Leuschner U
Eur J Clin Pharmacol; 1993; 45(3):221-5. PubMed ID: 8276045
[TBL] [Abstract][Full Text] [Related]
32. Therapy with ursodeoxycholic acid in cholestatic liver disease.
Van de Meeberg PC; van Erpecum KJ; van Berge-Henegouwen GP
Scand J Gastroenterol Suppl; 1993; 200():15-20. PubMed ID: 8016564
[TBL] [Abstract][Full Text] [Related]
33. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
Stiehl A; Rudolph G; Sauer P; Theilmann L
J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
[TBL] [Abstract][Full Text] [Related]
34. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis.
Trauner M; Wagner M; Fickert P; Zollner G
J Clin Gastroenterol; 2005 Apr; 39(4 Suppl 2):S111-24. PubMed ID: 15758646
[TBL] [Abstract][Full Text] [Related]
35. Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis: effect of ursodeoxycholic treatment.
Chretien Y; Poupon R; Gherardt MF; Chazouilleres O; Labbe D; Myara A; Trivin F
Gut; 1989 Aug; 30(8):1110-5. PubMed ID: 2767508
[TBL] [Abstract][Full Text] [Related]
36. Fibrates and cholestasis.
Ghonem NS; Assis DN; Boyer JL
Hepatology; 2015 Aug; 62(2):635-43. PubMed ID: 25678132
[TBL] [Abstract][Full Text] [Related]
37. New therapeutical indications of ursodeoxycholic acid.
Copaci I; Micu L; Iliescu L; Voiculescu M
Rom J Gastroenterol; 2005 Sep; 14(3):259-66. PubMed ID: 16200237
[TBL] [Abstract][Full Text] [Related]
38. Effect of colitis and ileoanal pouch on biliary enrichment of ursodeoxycholic acid in primary sclerosing cholangitis.
Rost D; Rudolph G; Kloeters-Plachky P; Stiehl A
Dig Dis Sci; 2006 Mar; 51(3):618-22. PubMed ID: 16614977
[TBL] [Abstract][Full Text] [Related]
39. Formation of iso-ursodeoxycholic acid during administration of ursodeoxycholic acid in man.
Beuers U; Fischer S; Spengler U; Paumgartner G
J Hepatol; 1991 Jul; 13(1):97-103. PubMed ID: 1918882
[TBL] [Abstract][Full Text] [Related]
40. Ursocholic acid, a hydrophilic bile acid, fails to improve liver function parameters in primary biliary cirrhosis: comparison with ursodeoxycholic acid.
Batta AK; Salen G; Abroon J
Am J Gastroenterol; 1997 Jun; 92(6):1035-7. PubMed ID: 9177526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
